anifrolumab lupus
Selected indexed studies
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus. (N Engl J Med, 2020) [PMID:31851795]
- Systemic Lupus Erythematosus: A Review. (JAMA, 2024) [PMID:38587826]
- A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. (Arthritis Rheumatol, 2023) [PMID:36369793]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus. (2020) pubmed
- Systemic Lupus Erythematosus: A Review. (2024) pubmed
- A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. (2023) pubmed
- Anifrolumab in systemic lupus erythematosus. (2023) pubmed
- Systemic lupus erythematosus. (2024) pubmed
- Anifrolumab for systemic lupus erythematosus. (2022) pubmed
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. (2017) pubmed
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. (2023) pubmed
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. (2019) pubmed